Effect of Pentoxifylline in treatment of schizophrenia

Phase 3

Recruiting

Conditions: Schizophrenia
schizophrenia.

Registration Number: IRCT20190914044769N1

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 52

Inclusion Criteria

Diagnosis of schizophrenia based on DSM-5 criteria
Patients aged 18-55 years
Completion of the consent form by the patient or his / her family
Education level at least eighth grade
Absence of other concurrent psychiatric disorders
Absence of liver and kidney disorders
Absence of medical illness leads to psychiatric symptoms
No substance use except for smoking
Absence of serious cognitive impairment
Absence of risk factor for bleeding
Patients who are prescribed antipsychotics for risperidone, olanzapine or aripiperazole.
Onset of illness under 45 years

Exclusion Criteria

Hypersensitivity reaction or any unbearable side effect caused by the drug
Unwillingness to continue taking the drug and continue the project

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive scores according to Stroop, Ray, Digit span, and Wisconcin card sorting test. Timepoint: Evaluation of cognitive impairments and positive and negative symptoms of schizophrenia at baseline (before intervention) and 4 and 8 weeks after starting pentoxifylline. Method of measurement: Positive and Negative Syndrome Scale, cognitive tests include Stroop, Ray, Digit span, and Wisconcin card sorting test.

Secondary Outcome Measures

Name	Time	Method
Score of Positive and Negative Syndrome Scale. Timepoint: Baseline (before intervention) and 4 and 8 weeks after starting pentoxifylline. Method of measurement: Positive and Negative Syndrome Scale.